Evidence map›Paper›PMID 32272732›Full record

ArticleCells2020

Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience.

Daniela Califano, Daniela Russo, Giosuè Scognamiglio, Nunzia Simona Losito, Anna Spina, Anna Maria Bello, Anna Capiluongo, Francesca Galdiero, Rossella De Cecio, Simona Bevilacqua and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Daniela CalifanoFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-6945-3209
Daniela RussoFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-9471-1935
Giosuè ScognamiglioSurgical Pathology Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Nunzia Simona LositoSurgical Pathology Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Anna SpinaFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Anna Maria BelloFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Anna CapiluongoFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Francesca GaldieroFunctional Genomic Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Rossella De CecioSurgical Pathology Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Simona BevilacquaClinical Trials Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Piera GargiuloClinical Trials Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Edoardo MarchesiIntegrated Biology Platform, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, 20133 Milan, Italy.
Silvana CanevariMolecular Therapies Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, 20133 Milan, Italy.
Francesco PerroneClinical Trials Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Gennaro DanieleClinical Trials Unit, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.
Loris De CeccoIntegrated Biology Platform, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, 20133 Milan, Italy.ORCID 0000-0002-7066-473X
Delia MezzanzanicaMolecular Therapies Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, 20133 Milan, Italy.ORCID 0000-0002-9664-6871
Sandro PignataUrogynaecological Medical Oncology Unit Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", 80131 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center's web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial's coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients' accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes.

Indexed as

FemaleHumansItalyOvarian NeoplasmsPrecision MedicineTime FactorsTranslational Research, Biomedicalbiomarkers definitionFFPE block collectiongynecological cancersprecision medicinetranslational studies design

Identifiers

PMID32272732
PMCPMC7226822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.